These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 29989040)
41. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study. Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T Am J Nephrol; 2021; 52(10-11):884-893. PubMed ID: 34569482 [TBL] [Abstract][Full Text] [Related]
42. A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study. Akizawa T; Nangaku M; Yamaguchi T; Koretomo R; Maeda K; Miyazawa Y; Hirakata H Kidney Dis (Basel); 2021 Nov; 7(6):494-502. PubMed ID: 34901195 [TBL] [Abstract][Full Text] [Related]
44. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis. Akizawa T; Yamaguchi Y; Otsuka T; Reusch M Nephron; 2020; 144(8):372-382. PubMed ID: 32580188 [TBL] [Abstract][Full Text] [Related]
45. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Provenzano R; Bhaduri S; Singh AK; Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787 [TBL] [Abstract][Full Text] [Related]
46. Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan. Nangaku M; Akizawa T; Nagakubo T; Yonekawa T; Kimura T; Endo Y; Cobitz A Ther Apher Dial; 2022 Dec; 26(6):1065-1078. PubMed ID: 35312234 [TBL] [Abstract][Full Text] [Related]
47. Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases. Yamasaki S; Horiuchi T Hematol Rep; 2023 Mar; 15(1):180-187. PubMed ID: 36975732 [TBL] [Abstract][Full Text] [Related]
48. Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia. Ariazi JL; Duffy KJ; Adams DF; Fitch DM; Luo L; Pappalardi M; Biju M; DiFilippo EH; Shaw T; Wiggall K; Erickson-Miller C J Pharmacol Exp Ther; 2017 Dec; 363(3):336-347. PubMed ID: 28928122 [TBL] [Abstract][Full Text] [Related]
50. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia. Thanakitcharu P; Siriwiwatanakul N J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706 [TBL] [Abstract][Full Text] [Related]
51. Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient. Goodkin DA; Zhao J; Cases A; Nangaku M; Karaboyas A Am J Nephrol; 2022; 53(5):333-342. PubMed ID: 35462377 [TBL] [Abstract][Full Text] [Related]
52. Ischemic Stroke During Daprodustat Therapy for Renal Anemia: A Report of Three Cases. Uchio N; Komaki S; Hao A; Matsumoto H Cureus; 2024 Apr; 16(4):e57990. PubMed ID: 38738133 [TBL] [Abstract][Full Text] [Related]
53. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568 [TBL] [Abstract][Full Text] [Related]
54. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Chen N; Qian J; Chen J; Yu X; Mei C; Hao C; Jiang G; Lin H; Zhang X; Zuo L; He Q; Fu P; Li X; Ni D; Hemmerich S; Liu C; Szczech L; Besarab A; Neff TB; Peony Yu KH; Valone FH Nephrol Dial Transplant; 2017 Aug; 32(8):1373-1386. PubMed ID: 28371815 [TBL] [Abstract][Full Text] [Related]
55. Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents. Silver MR; Geronemus R; Krause M; Chen CY; Kewalramani R; Stehman-Breen C Curr Med Res Opin; 2009 Jan; 25(1):123-31. PubMed ID: 19210145 [TBL] [Abstract][Full Text] [Related]
56. Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease. Ishii T; Tanaka T; Nangaku M Ther Clin Risk Manag; 2021; 17():155-163. PubMed ID: 33628028 [TBL] [Abstract][Full Text] [Related]
57. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Gupta N; Wish JB Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135 [TBL] [Abstract][Full Text] [Related]
58. Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis. Xie D; Wang J; Wu X; Li M Int Urol Nephrol; 2018 Dec; 50(12):2201-2206. PubMed ID: 30073615 [TBL] [Abstract][Full Text] [Related]
59. Carcinogenicity Assessment of Daprodustat (GSK1278863), a Hypoxia-Inducible Factor (HIF)-Prolyl Hydroxylase Inhibitor. Adams DF; Watkins MS; Durette L; Laliberté J; Goulet F; Debien E; Frazier KS; Mellal N; Chen L; Shi W; Thomas R; Hu E Toxicol Pathol; 2020 Feb; 48(2):362-378. PubMed ID: 31640478 [TBL] [Abstract][Full Text] [Related]
60. C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis. Bastos K; Lucarelli LA; De Francesco-Daher E; Filho RP; Henríquez C; Espinoza B; Villanueva I; Schwedt E; Schiavelli R; Correa-Rotter R Int Urol Nephrol; 2013 Oct; 45(5):1355-64. PubMed ID: 22990412 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]